SmileDirectClub, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US83192H1068
USD
0.00
0 (-100.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About SmileDirectClub, Inc. stock-summary
stock-summary
SmileDirectClub, Inc.
Pharmaceuticals & Biotechnology
SmileDirectClub, Inc. provides medical technology platform. The Company provides SmileCheck, which is a teledentistry platform for doctor monitoring and communication. The Company provides clear aligner therapy treatment through its teledentistry platform. Its aligner treatment addresses the orthodontics market. The Company has a network of approximately 240 orthodontists and general dentists across the United States, Puerto Rico, Canada, Australia and the United Kingdom. The Company provides customer care to its members through a variety of communication channels, including its Website, phone, chat, e-mail and social media. SmileCheck platform is a central data repository for all medical records, business transactions and member communications. SmileCheck provides online portal that allows for remote access to treatment plan information. The Company offers aligners, impression kits, whitening gel and retainers.
Company Coordinates stock-summary
Company Details
414 Union St , NASHVILLE TN : 37219-1757
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 15 Schemes (7.99%)

Foreign Institutions

Held by 49 Foreign Institutions (4.39%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Katzman
Chairman of the Board, Chief Executive Officer
Mr. Alexander Fenkell
Co-Founder, Director
Mr. Jordan Katzman
Co-Founder, Director
Mr. Steven Katzman
Chief Operating Officer, Director
Ms. Susan Rammelt
Chief Legal Officer, Executive Vice President- Business, General Counsel, Secretary, Director
Dr. William Frist
Director
Ms. Carol Hamilton
Director
Mr. Richard Schnall
Director
Mr. Richard Wallman
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
102 Million
(Quarterly Results - Jun 2023)
Net Profit:
-54 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.72

stock-summary
Return on Equity

-273.42%

stock-summary
Price to Book

0.00